Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Thiopurines have been a cornerstone in the treatment of inflammatory bowel disease (IBD). Although they have been used for more than 50 years, there are still some unsolved issues about their efficacy and, also, some safety concerns, mainly the risk of myelosuppression and life-threatening lymphopro...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollón
Format:	Artikel
Sprache:	English
Veröffentlicht:	Frontiers Media S.A. 2021-07-01
Schriftenreihe:	Frontiers in Medicine
Schlagworte:	thiopurines inflammatory bowel disease pharmacogenomics toxicity indications optimize
Online Zugang:	https://www.frontiersin.org/articles/10.3389/fmed.2021.681907/full

Ähnliche Einträge

Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease
von: Oliwia Zakerska-Banaszak, et al.
Veröffentlicht: (2022-03-01)

Epstein-Barr Virus Infection and Thiopurine Therapy in a Pediatric Population with Inflammatory Bowel Disease
von: Maria Do Céu Espinheira, et al.
Veröffentlicht: (2020-04-01)

Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)
von: Kang-Moon Lee, et al.
Veröffentlicht: (2015-07-01)

Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluationResearch in context
von: Georgina Nakafero, et al.
Veröffentlicht: (2023-10-01)

Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases
von: Keiichi Tominaga, et al.
Veröffentlicht: (2021-01-01)

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
von: Raphael P. Luber, et al.
Veröffentlicht: (2019-11-01)

What Happens to Patients with Inflammatory Bowel Disease Who Are Intolerant to Thiopurines?
von: Helena Gensmyr-Singer, et al.
Veröffentlicht: (2024-06-01)

Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilization in Singapore
von: Jia Qi Yeo, et al.
Veröffentlicht: (2022-10-01)

gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
von: Katsuyoshi Matsuoka
Veröffentlicht: (2020-07-01)

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
von: Shunsuke Komoto, et al.
Veröffentlicht: (2016-04-01)

Plasma lipidomic profiling of thiopurine-induced leukopenia after NUDT15 genotype-guided dosing in Chinese IBD patients
von: Pan Li, et al.
Veröffentlicht: (2023-06-01)

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
von: Jack S. Cornish, et al.
Veröffentlicht: (2020-01-01)

Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods
von: Edvin Brusač, et al.
Veröffentlicht: (2019-09-01)

Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
von: Sheng Zhang Lim, et al.
Veröffentlicht: (2018-10-01)

Nudix Hydroxylase 15 Mutations Strongly Predict Thiopurine-Induced Leukopenia Across Different Asian Ethnicities: Implications for Screening in a Diverse Population
von: Xin-Hui Khoo, et al.
Veröffentlicht: (2022-08-01)

Use of thiopurines in inflammatory bowel disease: an update
von: Arshdeep Singh, et al.
Veröffentlicht: (2022-01-01)

Thiopurine S-methyl Transferase (TPMT) Enzyme Level in Healthy Sudanese Population
von: Rayan Khalid, et al.
Veröffentlicht: (2024-09-01)

A Practical Non-Extraction Direct Liquid Chromatography Method for Determination of Thiopurine S-Methyltransferase Activity in Inflammatory Bowel Disease
von: Fariborz Bahrehmand, et al.
Veröffentlicht: (2017-08-01)

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response
von: Abaji R, et al.
Veröffentlicht: (2017-05-01)

Thiopurine-S-Methyltransferase Gene Polymorphism and Drug-related Toxicity in Children Treated for Acute Leukemia and Non-Hodgkin’s Lymphoma
von: Eda Ataseven, et al.
Veröffentlicht: (2022-03-01)

Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience
von: Takuya Yoshino, et al.
Veröffentlicht: (2015-07-01)

Severe Complication of Thiopurine Treatment in a Young Woman with Crohn’s Disease
von: Michiel PJ Voet, et al.
Veröffentlicht: (2021-03-01)

Thiopurine S-Methyltransferase and Methylenetetrahydrofolate Reductase Polymorphisms in Leukemia
von: Serhan Küpeli
Veröffentlicht: (2015-05-01)

Common Polymorphism’s Analysis of Thiopurine S-Methyltransferase (TPMT) in Iranian Population
von: Mehdi Azad, et al.
Veröffentlicht: (2009-01-01)

Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population
von: Hamza Ben Zeglam, et al.
Veröffentlicht: (2015-03-01)

Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study
von: Beatriz Sicilia, et al.
Veröffentlicht: (2021-06-01)

Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
von: Satoshi Yamada, et al.
Veröffentlicht: (2015-07-01)

Analytical and Sample Preparation Protocol for Therapeutic Drug Monitoring of 12 Thiopurine Metabolites Related to Clinical Treatment of Inflammatory Bowel Disease
von: Daniel Pecher, et al.
Veröffentlicht: (2018-07-01)

Personalization of thiopurine therapy: Current recommendations and future perspectives
von: Urbančič Dunja, et al.
Veröffentlicht: (2024-09-01)

The role of polymorphisms of thiopurine methyltransferase in therapy with Azathioprine: preliminary study
von: Francesca Mortillaro, et al.
Veröffentlicht: (2018-11-01)

Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients
von: Liang Ding, et al.
Veröffentlicht: (2021-05-01)

A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population
von: Kok-Siong Poon, et al.
Veröffentlicht: (2022-04-01)

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia
von: Xiaohong Wang, et al.
Veröffentlicht: (2024-07-01)

Usefulness and difficulties with the thiopurine pharmacogenomic NUDT15 genotyping test: Analysis of real-world data in Japan
von: Yoichi Kakuta, et al.
Veröffentlicht: (2023-11-01)

TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learned
von: Liuh Ling Goh, et al.
Veröffentlicht: (2022-09-01)

6-methylmercaptopurine riboside, a thiopurine nucleoside with antiviral activity against canine distemper virus in vitro
von: Otávio Valério de Carvalho, et al.
Veröffentlicht: (2017-06-01)

Immunosuppressants in modern approaches to treatment of inflammatory bowel diseases
von: O. B. Schukina, et al.
Veröffentlicht: (2013-05-01)

Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
von: Loulieta Nazerai, et al.
Veröffentlicht: (2023-12-01)

Association between the c.415C > T, c.52G > A, and 36_37insGGAGTC polymorphisms of NUDT 15 and thiopurine-induced leukopenia, thiopurine intolerance, and severe hair loss: an updated meta-analysis
von: Wang R, et al.
Veröffentlicht: (2019-08-01)

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
von: Davide Giuseppe Ribaldone, et al.
Veröffentlicht: (2019-08-01)